Stryker faces investigation after CEO reveals ongoing manufacturing issues, stock drops 8.8%.

Stryker Corp is under investigation by Pomerantz LLP for potential securities fraud after the company's CEO disclosed unresolved manufacturing problems affecting inventory in its peripheral vascular business. This issue, initially expected to be resolved by Q3 2026, is now anticipated to continue into Q4, causing the stock price to fall nearly 9% on September 8, 2026. The investigation will determine if Stryker and its executives engaged in unlawful practices. Investors affected are encouraged to contact Pomerantz LLP for class action participation.

As of Sep 25, 2026 04:41 WIB, Stryker Corporation (SYK) trades on Pluang at USD 270.48 with a 1-day change of -1.07%. The stock's market capitalization stands at $104.87 billion, reflecting its significant presence in the health sector. Notably, the typical hold time for SYK on Pluang is 21 days, indicating investor engagement with this stock.